A61K 31 - Medicinal preparations containing organic active ingredients

Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912)
10/2006
10/19/2006	CA2603402A1 Compositions of an orally active 1,2,4-oxadiazole for nonsense mutation suppression therapy
10/19/2006	CA2603320A1 Pyridylmethylsulfone derivative
10/19/2006	CA2603254A1 New bicyclic angiotensin ii agonists
10/19/2006	CA2603206A1 Compositions and their uses directed to acetyl-coa carboxylases
10/19/2006	CA2603204A1 Aminopyrazole derivatives, their manufacture and use as pharmaceutical agents
10/19/2006	CA2603189A1 Injectable depot formulations and methods for providing sustained release of poorly soluble drugs comprising nanoparticles
10/19/2006	CA2602968A1 Crystals of morphinan derivative and process for producing the same
10/19/2006	CA2602812A1 Combined use of prostaglandin compound and proton pump inhibitor for the treatment of gastrointestinal disorders
10/19/2006	CA2602721A1 4-(pyrid-2-yl) amino substituted pyrimidine as protein kinase inhibitors
10/19/2006	CA2602626A1 Method of treating schizophrenia prodrome
10/19/2006	CA2602549A1 Anti-inflammatory modalities
10/19/2006	CA2602303A1 Tricyclic azole derivatives, their manufacture and use as pharmaceutical agents
10/19/2006	CA2602197A1 Inhibitors of akt activity
10/19/2006	CA2602146A1 Mitotic kinesin inhibitors
10/19/2006	CA2601990A1 Organic compounds
10/19/2006	CA2601986A1 1h-quinaz0line-2,4-diones and their use as ampa-receptor ligands
10/19/2006	CA2600709A1 Use of cd25 antibodies in immunotherapy
10/19/2006	CA2598578A1 Antitumor combination comprising substituted acryloyl distamycin derivatives and antibodies inhibiting growth factors or their receptors
10/19/2006	CA2598208A1 Tetrahydronaphthalene derivatives, processes for their preparation and their use as antiinflammatory agents
10/19/2006	CA2598207A1 Substituted chroman derivatives, method for the production and the use thereof in the form of antiphlogistics
10/19/2006	CA2584075A1 Combined treatment with radiation and an epidermal growth factor receptor kinase inhibitor
10/19/2006	CA2583520A1 Combined treatment with bortezomib and an epidermal growth factor receptor kinase inhibitor
10/19/2006	CA2574514A1 Phosphonate analogs of hiv inhibitor compounds
10/19/2006	CA2572207A1 Solid forms of linezolid and processes for preparation thereof
10/19/2006	CA2544038A1 Pharmaceutical compositions for the treatment of ulcerations
10/18/2006	EP1713063A2 A printable audio format
10/18/2006	EP1712642A1 Method of examining sensitivity of cancer cell to anticancer agent
10/18/2006	EP1712628A2 Compounds and methods for immunotherapy and diagnosis of tuberculosis
10/18/2006	EP1712557A1 New s-adenosyl-L-methionine analogues with extended activated groups for transfer by methyltransferases
10/18/2006	EP1712556A1 Azithromycin monohydrate
10/18/2006	EP1712555A1 Prodrug comprising 5-aminosalicylate glycoside
10/18/2006	EP1712554A1 Pyridobenzoxazine derivative
10/18/2006	EP1712553A2 Derivates of [6, 7-dihydro - 5H - imidazo[1,2- alpha]imidazole-3-sulfonylamino]-propionamide and their use as inhibitors upon the interaction of CAMS and leukointegrins
10/18/2006	EP1712550A2 Substituted triazole diamine derivatives as kinase inhibitors
10/18/2006	EP1712548A2 5-amino-4-hydroxy-7-(pyridinylmethyl)-alkanamide derivatives and related compounds as renin inhibitors for the treatment of hypertension
10/18/2006	EP1712547A1 Bicycloester derivative
10/18/2006	EP1712242A1 Method of regulating phosphorylation of sr protein and antiviral agents comprising sr protein activity regulator as the active ingredient
10/18/2006	EP1712238A1 Anthracyclin induced immunogenic dead or dying cells composition
10/18/2006	EP1712237A2 Erythropoietin solution preparation stabilized with leucine, glutamic acid or lysine
10/18/2006	EP1712236A2 Methods of treating acne
10/18/2006	EP1712235A2 Combinational therapy involving a small molecule inhibitor of the MDM2: P53 interaction
10/18/2006	EP1712234A1 Use of 4-Pyridylmethylphthalazines for Cancer Treatment
10/18/2006	EP1712233A1 Aqueous solution containing pyrazoloacridone derivative
10/18/2006	EP1712232A1 Compositions for treating allergic rhinitis and other disorders using descarboethoxyloratadine
10/18/2006	EP1712231A2 Method for improving the pharmacokinetics of tipranavir
10/18/2006	EP1712230A1 Pharmaceutical composition for xerophthalmia and xerostomia treatment
10/18/2006	EP1712229A1 Fluconazole-tinidazole combination for the treatment of vaginal infections, composition thereof and preparation and use of same
10/18/2006	EP1712228A2 Hyaluronic acid derivatives for the prevention and treatment of cutaneous scars
10/18/2006	EP1712227A1 Amino diols useful in the treatment of Alzheimer's disease
10/18/2006	EP1712226A2 Treatment of a Hemoglobinopathy
10/18/2006	EP1712225A1 Substituted carbostyril derivatives as 5-HT 1A receptor subtype agonists
10/18/2006	EP1712220A1 Pharmaceutical aerosol composition
10/18/2006	EP1711635A1 Genes associated with canine osteoarthritis and related methods and compositions
10/18/2006	EP1711634A2 Naphthalimide dosing by n-acetyl transferase genotyping
10/18/2006	EP1711622A2 Genetic polymorphisms associated with cardiovascular disorders and drug response, methods of detection and uses thereof
10/18/2006	EP1711617A1 Method and compositions for identifying anti-hiv therapeutics compounds
10/18/2006	EP1711595A2 Use of polysulphated alginate in cellular matrices
10/18/2006	EP1711508A1 6r-(3,6-dideoxy-l-arabino-hexopyranosyloxy)heptanoic acid, preparation process for the same and dauer effect thereof
10/18/2006	EP1711507A1 Crystalline form of risedronate monosodium
10/18/2006	EP1711500A1 Diaza- or thiazadione derivatives with neuroprotective activity
10/18/2006	EP1711499A2 Fused pyrrolocarbazoles and methods for the preparation thereof
10/18/2006	EP1711497A1 2-(3-substituted-aryl)amino-4-aryl-thiazoles as tyrosine kinase inhibitors
10/18/2006	EP1711496A1 Thiazole compounds
10/18/2006	EP1711495A2 Quinoline, quinazoline, pyridine and pyrimidine counds and their use in the treatment of inflammation, angiogenesis and cancer
10/18/2006	EP1711494A1 Aryl substituted heterocycles, method for production and use thereof as medicaments
10/18/2006	EP1711493A2 Crystalline forms of zolmitriptan
10/18/2006	EP1711492A1 Substituted quinolines and their use as mycobacterial inhibitors
10/18/2006	EP1711491A1 Heterocyclic derivatives as gpcr receptor agonists
10/18/2006	EP1711488A1 Heterocyclic modulators of the glucocorticoid receptor, ap-1, and/or nf-kappa b activity and use thereof
10/18/2006	EP1711487A1 Dehydrophenylahistins and analogs thereof and the synthesis of dehydrophenylahistins and analogs thereof
10/18/2006	EP1711486A2 Bis-indole pyrroles useful as antimicrobials agents
10/18/2006	EP1711485A1 Amino-benzimidazoles derivatives as inhibitors of respiratory syncytial virus replication
10/18/2006	EP1711484A1 Synthesis of cyanoimino-benzoimidazoles
10/18/2006	EP1711480A1 Novel long-working beta-2-agonists and use thereof as medicaments
10/18/2006	EP1711478A2 Benzo [d]isoxazol-3-ol daao inhibitors
10/18/2006	EP1711477A1 Novel crystalline forms of an inhibitor of 11-beta-hydroxysteroid dehydrogenase type 1
10/18/2006	EP1711476A2 Pyrimidyl phosphonate antiviral compounds and methods of use
10/18/2006	EP1711475A1 2-(phenylamino)-pyrimidin-5-amides as cannabinoid 2 receptors modulators for the treatment of immune or inflammatory disorders.
10/18/2006	EP1711473A1 Substituted n-cyclohexylimidazolinones having an mch-modulatory effect
10/18/2006	EP1711470A1 Malonamide derivatives blocking the activtiy of gamma-secretase
10/18/2006	EP1711468A1 Process for preparing purified ciprofloxacin
10/18/2006	EP1711467A2 Quinoline intermediates of receptor tyrosine kinase inhibitors and the synthesis thereof
10/18/2006	EP1711465A1 Hydroisoindoline tachykinin receptor antagonists
10/18/2006	EP1711462A1 Proline derivatives used as pharmaceutical active ingredients for the treatment of tumours
10/18/2006	EP1711461A2 N-deacetylthiocolchicine derivatives, their use and pharmaceutical formulations containing them
10/18/2006	EP1711459A1 Nitric oxide releasing prodrugs of diaryl-2-(5h)-furanones as cyclooxygenase-2 inhibitors
10/18/2006	EP1711457A1 Nitric oxide releasing prodrugs of diaryl-2-(5h)-furanones as cyclooxygenase-2 inhibitors
10/18/2006	EP1711456A2 Amino alcohol derivatives and their use as renin inhibitors
10/18/2006	EP1711455A2 Facially amphiphilic polyaryl and polyarylalkynyl polymers and oligomers and uses thereof
10/18/2006	EP1711454A1 Combination therapy for treating cyclooxygenase-2 mediated diseases or conditions in patients at risk of thrombotic cardiovascular events
10/18/2006	EP1711230A1 Use of epothilones in the treatment of neuronal connectivity defects such as schizophrenia and autism
10/18/2006	EP1711210A2 Combined use of prame inhibitors and hdac inhibitors
10/18/2006	EP1711209A1 Methods of treating mesothelioma using an antisense oligonucleotide to thymidylate synthase
10/18/2006	EP1711203A1 Targeted atherosclerosis treatment
10/18/2006	EP1711200A2 Type ii diabetes
10/18/2006	EP1711197A1 Methods and compositions for the prevention and treatment of inflammatory diseases or conditions
10/18/2006	EP1711190A1 Agent for treating inflammatory diseases
10/18/2006	EP1711189A2 6,11-3c-bicyclic 8a-azalide derivatives
10/18/2006	EP1711188A2 Anti-cancer therapies
10/18/2006	EP1711187A2 Reducing arthritis and lameness in subjects by growth hormone releasing hormone (ghrh) supplementation

1 ... 4046 4047 4048 4049 4050 4051 4052 4053 4054 4055 4056 4057 4058 4059 4060 4061 4062 4063 4064 4065 4066 ... 7860